Terry Rosen

Terry Rosen, Ph.D. is currently the CEO of Arcus Biosciences. He previously served as CEO of Flexus Biosciences, which was acquired by BMS in 2015. Prior to co-founding Flexus in October of 2013, Dr. Rosen served as Vice President, Therapeutic Discovery (TD) at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004. Dr. Rosen held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry. He has also held scientific and management positions at Pfizer and Abbott Laboratories. Dr. Rosen serves on the Salk Institute Board of Trustees, the leadership committees of the University of Michigan Undergraduate Research Opportunity Program and Life Sciences Institute, the Berkeley Chemistry Advisory Board, the Caltech Biology and Biology and Biological Engineering Chair’s Council and the California Life Sciences Association Board. He holds a B.S. in Chemistry from the University of Michigan and a Ph.D. in Organic Chemistry from the University of California, Berkeley.